Skip to main content
. 2014 May 27;32(31):3917–3926. doi: 10.1016/j.vaccine.2014.05.052

Fig. 4.

Fig. 4

Prevention of CVB3 myocarditis and protection against CVB3 challenge by intranasal immunization with VSV-based vaccine or DNA in chitosan formulations. Seven days after 3LD50 CVB3 challenge, (A) body weight loss, (B) serum CK, (C) CK-MB, (D) Viral titers in heart and (E) inflammation of HE-stained sections were measured as indicated by the arrows. The results are represented as the mean ± SD (n = 6) of three separate experiments.*P < 0.05; **P < 0.01; ***P < 0.001.